Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival

• Verfasst von: Niyazi, Karim-Maximilian [VerfasserIn]
• Verfasst von: Adeberg, Sebastian [VerfasserIn]
• Verfasst von: Bougatf, Nina [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Titel: Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival
• Titelzusatz: a multicenter DKTK/ROG analysis
• Verf.angabe: Maximilian Niyazi, Sebastian Adeberg, David Kaul, Anne-Laure Boulesteix, Nina Bougatf, Daniel F. Fleischmann, Arne Grün, Anna Krämer, Claus Rödel, Franziska Eckert, Frank Paulsen, Kerstin A. Kessel, Stephanie E. Combs, Oliver Oehlke, Anca-Ligia Grosu, Annekatrin Seidlitz, Annika Lattermann, Mechthild Krause, Michael Baumann, Maja Guberina, Martin Stuschke, Volker Budach, Claus Belka, Jürgen Debus
• E-Jahr: 2018
• Jahr: 9 February 2018
• Umfang: 7 S.
• Illustrationen: Diagramme
• Fussnoten: Gesehen am 04.12.2019
• Titel Quelle: Enthalten in: Radiotherapy and oncology
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1983
• Jahr Quelle: 2018
• Band/Heft Quelle: 127(2018), 1, Seite 121-127
• ISSN Quelle: 1879-0887
• DOI: doi:10.1016/j.radonc.2018.01.011
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Glioblastoma
• Sach-SW: High-grade glioma
• Sach-SW: Reirradiation
• Sach-SW: RRRS
• Sach-SW: Score
• K10plus-PPN: 168418486X

Abstract

Background and purpose - Reirradiation (reRT) is a valid option with considerable efficacy in patients with recurrent high-grade glioma, but it is still not known which patients might be optimal candidates for a second course of irradiation. This study validated a newly developed prognostic score independently in an external patient cohort. - Material and methods - The reRT risk score (RRRS) is based on a linear combination of initial histology, clinical performance status, and age derived from a multivariable model of 353 patients. This score can predict post-recurrence survival (PRS) after reRT. The validation dataset consisted of 212 patients. - Results - The RRRS differentiates three prognostic groups. Discrimination and calibration were maintained in the validation group. Median PRS times in the development cohort for the good/intermediate/poor risk categories were 14.2, 9.1, and 5.3months, respectively. The respective groups within the validation cohort displayed median PRS times of 13.8, 8.8, and 3.8months, respectively. Uno’s C for development data was 0.64 (CI: 0.60-0.69) and for validation data 0.63 (CI: 0.58-0.68). - Conclusions - The RRRS has been successfully validated in an independent patient cohort. This linear combination of three easily determined clinicopathological factors allows for a reliable classification of patients and may be used as stratification factor for future trials.